NASDAQ:BBOT BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis $5.52 -1.24 (-18.34%) Closing price 09/10/2026 04:00 PM EasternExtended Trading$5.40 -0.12 (-2.25%) As of 07:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About BridgeBio Oncology Therapeutics Stock (NASDAQ:BBOT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BBOT alerts:Sign Up Key Stats Today's Range$5.48▼$6.7950-Day Range$5.52▼$9.6052-Week Range$5.48▼$14.87Volume2.79 million shsAverage Volume307,644 shsMarket Capitalization$442.54 millionP/E RatioN/ADividend YieldN/APrice Target$23.13Consensus RatingModerate Buy Company Overview BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need. BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development. Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here. Prospective investors and researchers should consult the company’s SEC filings, investor presentations and official disclosures for up-to-date details on its pipeline, management team and strategic priorities.AI Generated. May Contain Errors. Read More BridgeBio Oncology Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreBBOT MarketRank™: BridgeBio Oncology Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 324th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBridgeBio Oncology Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialBridgeBio Oncology Therapeutics has a consensus price target of $23.13, representing about 318.9% upside from its current price of $5.52.Amount of Analyst CoverageBridgeBio Oncology Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BridgeBio Oncology Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BridgeBio Oncology Therapeutics are expected to grow in the coming year, from ($2.79) to ($2.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Oncology Therapeutics is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Oncology Therapeutics is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBridgeBio Oncology Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.22% of the float of BridgeBio Oncology Therapeutics has been sold short.Short Interest Ratio / Days to CoverBridgeBio Oncology Therapeutics has a short interest ratio ("days to cover") of 20.77, which indicates bearish sentiment.Change versus previous monthShort interest in BridgeBio Oncology Therapeutics has recently increased by 6.63%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBridgeBio Oncology Therapeutics does not currently pay a dividend.Dividend GrowthBridgeBio Oncology Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.01 News SentimentBridgeBio Oncology Therapeutics has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for BridgeBio Oncology Therapeutics this week, compared to 2 articles on an average week.Search Interest3 people have searched for BBOT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BridgeBio Oncology Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.40% of the stock of BridgeBio Oncology Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.89% of the stock of BridgeBio Oncology Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BridgeBio Oncology Therapeutics' insider trading history. Receive BBOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Oncology Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBOT Stock News HeadlinesWedbush Reiterates Outperform Rating for BridgeBio Oncology Therapeutics (NASDAQ:BBOT)September 11 at 1:18 AM | americanbankingnews.comBBOT Reports BBO-8520 Data in NSCLC, Highlights Combination ResultsSeptember 8 at 6:13 PM | marketscreener.comMALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 11 at 1:00 AM | Weiss Ratings (Ad)BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant CancersSeptember 8 at 4:05 PM | globenewswire.comBBOT to Participate in Upcoming Investor Healthcare ConferencesSeptember 1, 2026 | globenewswire.comBridgeBio Oncology Q2 Loss WidensAugust 12, 2026 | finance.yahoo.comBridgeBio Oncology Therapeutics, Inc.: BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate ProgressAugust 12, 2026 | finanznachrichten.deBridgeBio Oncology Therapeutics, Inc. (BBOT)August 11, 2026 | finance.yahoo.comSee More Headlines BBOT Stock Analysis - Frequently Asked Questions How have BBOT shares performed this year? BridgeBio Oncology Therapeutics' stock was trading at $11.50 at the start of the year. Since then, BBOT stock has decreased by 52.0% and is now trading at $5.52. How were BridgeBio Oncology Therapeutics' earnings last quarter? BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) issued its quarterly earnings results on Tuesday, August, 11th. The company reported ($705.20) earnings per share (EPS) for the quarter. Who are BridgeBio Oncology Therapeutics' major shareholders? BridgeBio Oncology Therapeutics' top institutional shareholders include Wellington Management Group LLP (3.48%), Opaleye Management Inc. (0.87%), Tema ETFs LLC (0.12%) and Tidal Investments LLC (0.12%). How do I buy shares of BridgeBio Oncology Therapeutics? Shares of BBOT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today9/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BBOT's financial health is in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BBOT CIK1869105 Webbbotx.com Phone(857) 702-0377FaxN/AEmployeesN/AYear Founded2025Price Target and Rating Average Price Target for BridgeBio Oncology Therapeutics$23.13 High Price Target$29.00 Low Price Target$15.00 Potential Upside/Downside+318.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$134.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-46.90% Return on Assets-42.17% Debt Debt-to-Equity RatioN/A Current Ratio4.69 Quick Ratio4.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.14 per share Price / Book1.07Miscellaneous Outstanding Shares80,170,000Free Float60,612,000Market Cap$442.54 million OptionableN/A Beta0.38 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:BBOT) was last updated on 9/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Oncology Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Oncology Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
